One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
STERIS plc (STE): score, valuation & FAQ
STERIS plc (STE) is a Medical Devices company that scores 70.1 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
On valuation, STE sits about 21% above our discounted-cash-flow fair value — the current price implies roughly 11% annual free-cash-flow growth over the next decade.
Is STE a good stock to buy?
Bull Rankings scores STE 70.1 out of 100 on its quality-growth model, which is a solid, above-average reading. A score is a quantitative screen of STERIS plc's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does STE score 70.1 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). STE grades middle-of-pack across the strip. Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is STE overvalued or undervalued?
Based on $217.84, STE sits about 21% above our discounted-cash-flow fair value — the current price implies roughly 11% annual free-cash-flow growth over the next decade. It trades at a 27.4x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in STE?
A bear sees the valuation stretched: the P/E of 27.4 exceeds the sector median, and the Bull Rankings model assumes an 11% annual free‑cash‑flow growth—well above the 8.7% revenue growth, suggesting optimism is baked in. Any slowdown in hospital capex or a successful cost‑cutting push by rivals could compress margins, and a rise in debt‑to‑equity above the current 0.29 would trigger a re‑rating. The bear case materializes if free cash flow growth falls below 8% and the stock slides toward its 52‑week low of $195.14.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.